Highlights Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
11.56 ^USD	+4.81%		-0.86%	+119.77%

Apr. 29	Stoke Therapeutics Appoints Thomas Leggett CFO	MT
Apr. 29	Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024	Apr. 29	CI
Top Premarket Gainers	Mar. 26	MT
Stoke Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Stoke Therapeutics, Inc Announces New Data that Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome	Mar. 25	CI
Stoke Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Stoke Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (STOK) STOKE THERAPEUTICS Posts Q3 Revenue $3.3M	Nov. 07	MT
Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome	23-09-05	CI
Stoke Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Stoke Therapeutics, Inc. Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (Monarch & Adolescents with Dravet Syndrome	23-07-25	CI
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $5.2M	23-05-04	MT
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Stoke Therapeutics Secures UK Regulator's Approval to Initiate Phase 1/2 Study of STK-002	23-04-25	MT
Stoke Therapeutics Announces FDA Will Allow the Administration of Higher Single Dose of STK-001 in the Ongoing Phase 1/2a Monarch Study of Children and Adolescents with Dravet Syndrome	23-03-15	CI
STOKE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-06	AQ
Stoke Therapeutics' Q4 Net Loss Narrows -- Shares Gain Pre-Bell	23-03-06	MT
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q4 Revenue $3.3M	23-03-06	MT
Stoke Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Highlights

Filters